ES2391704T3 - Inhibidores de cinasa AKT y P70 S6 - Google Patents

Inhibidores de cinasa AKT y P70 S6 Download PDF

Info

Publication number
ES2391704T3
ES2391704T3 ES09744896T ES09744896T ES2391704T3 ES 2391704 T3 ES2391704 T3 ES 2391704T3 ES 09744896 T ES09744896 T ES 09744896T ES 09744896 T ES09744896 T ES 09744896T ES 2391704 T3 ES2391704 T3 ES 2391704T3
Authority
ES
Spain
Prior art keywords
imidazol
piperidin
ethyl
pyrimidin
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09744896T
Other languages
English (en)
Spanish (es)
Inventor
Robert Dean Dally
Sajan Joseph
Timothy Alan Shepherd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2391704T3 publication Critical patent/ES2391704T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES09744896T 2008-11-11 2009-11-03 Inhibidores de cinasa AKT y P70 S6 Active ES2391704T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11327308P 2008-11-11 2008-11-11
US113273P 2008-11-11
PCT/US2009/063020 WO2010056563A1 (en) 2008-11-11 2009-11-03 Akt and p70 s6 kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2391704T3 true ES2391704T3 (es) 2012-11-29

Family

ID=41402451

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09744896T Active ES2391704T3 (es) 2008-11-11 2009-11-03 Inhibidores de cinasa AKT y P70 S6

Country Status (36)

Country Link
US (1) US8148387B2 (OSRAM)
EP (1) EP2358710B1 (OSRAM)
JP (1) JP5432275B2 (OSRAM)
KR (1) KR101334460B1 (OSRAM)
CN (1) CN102216302B (OSRAM)
AR (1) AR074072A1 (OSRAM)
AU (1) AU2009314324B2 (OSRAM)
BR (1) BRPI0921916A2 (OSRAM)
CA (1) CA2743019C (OSRAM)
CO (1) CO6382114A2 (OSRAM)
CR (1) CR20110240A (OSRAM)
CY (1) CY1113409T1 (OSRAM)
DK (1) DK2358710T3 (OSRAM)
DO (1) DOP2011000129A (OSRAM)
EA (1) EA018947B1 (OSRAM)
EC (1) ECSP11011048A (OSRAM)
ES (1) ES2391704T3 (OSRAM)
HN (1) HN2011001247A (OSRAM)
HR (1) HRP20120738T1 (OSRAM)
IL (1) IL211940A (OSRAM)
JO (1) JO2822B1 (OSRAM)
MA (1) MA32776B1 (OSRAM)
MX (1) MX2011005000A (OSRAM)
MY (1) MY161461A (OSRAM)
NZ (1) NZ592062A (OSRAM)
PA (1) PA8846901A1 (OSRAM)
PE (1) PE20110807A1 (OSRAM)
PL (1) PL2358710T3 (OSRAM)
PT (1) PT2358710E (OSRAM)
RS (1) RS52520B (OSRAM)
SI (1) SI2358710T1 (OSRAM)
TN (1) TN2011000207A1 (OSRAM)
TW (1) TWI422587B (OSRAM)
UA (1) UA100190C2 (OSRAM)
WO (1) WO2010056563A1 (OSRAM)
ZA (1) ZA201102549B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5680638B2 (ja) 2009-07-02 2015-03-04 サノフイ 新規な(6−オキソ−1,6−ジヒドロピリミジン−2−イル)アミド誘導体、この調製およびakt(pkb)リン酸化インヒビターとしてのこの医薬的な使用
EP2491032B1 (en) 2009-10-23 2014-04-16 Eli Lilly and Company Akt inhibitors
JP5906303B2 (ja) 2011-04-07 2016-04-20 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH Aktキナーゼ阻害剤としてのイミダゾピリダジン類
EP2730575B1 (en) * 2011-07-09 2015-09-16 Xuanzhu Pharma Co., Ltd. Crystal form i of salt of dipeptidyl peptidase-iv inhibitor and preparation method and use thereof
US9145392B2 (en) 2011-09-12 2015-09-29 Merck Patent Gmbh Imidazole amines as modulators of kinase activity
BR112014005468A2 (pt) 2011-09-12 2017-03-21 Merck Patent Gmbh derivados de aminopiridina para uso como moduladores de atividade quinase
JP6280130B2 (ja) * 2012-11-16 2018-02-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung キナーゼ活性のモジュレーターとしての新規イミダゾール−ピペリジニル誘導体
ES2620119T3 (es) * 2012-11-16 2017-06-27 Merck Patent Gmbh Derivados heterocíclicos novedosos como moduladores de la actividad de quinasa
MX370448B (es) * 2013-03-11 2019-12-13 Merck Patent Gmbh Derivados de 6- [4- (1h-imidazol-2-il) piperidin-1-il] pirimidin-4-amina como moduladores de la actividad de cinasa.
RU2690679C2 (ru) * 2014-02-11 2019-06-05 Мерк Патент Гмбх Новые пиримидинимидазоламины в качестве модуляторов активности киназы
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Cgrp受體拮抗劑
JP6576553B2 (ja) * 2016-05-20 2019-09-18 大鵬薬品工業株式会社 新規5H−ピロロ[2,3−d]ピリミジン−6(7H)−オン誘導体
AU2021238799A1 (en) * 2020-03-17 2022-09-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused bicyclic derivative, preparation method therefor, and pharmaceutical use thereof
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
WO2023041061A1 (zh) 2021-09-17 2023-03-23 江苏恒瑞医药股份有限公司 一种稠合二环类衍生物的可药用盐、晶型及其制备方法
JPWO2024009977A1 (OSRAM) * 2022-07-05 2024-01-11

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1750727A2 (en) 2004-04-23 2007-02-14 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス, インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター(p70S6K、Akt−1およびAkt−2)としての[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジンまたは[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジン化合物
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
JP5606734B2 (ja) 2006-04-25 2014-10-15 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
SI2358710T1 (sl) 2012-11-30
MX2011005000A (es) 2011-05-25
CO6382114A2 (es) 2012-02-15
ZA201102549B (en) 2012-09-26
PE20110807A1 (es) 2011-10-31
CA2743019C (en) 2013-08-13
KR101334460B1 (ko) 2013-12-02
PT2358710E (pt) 2012-10-01
ECSP11011048A (es) 2011-06-30
JP2012508274A (ja) 2012-04-05
HK1158203A1 (en) 2012-07-13
IL211940A (en) 2014-01-30
CN102216302B (zh) 2013-08-21
EP2358710A1 (en) 2011-08-24
AR074072A1 (es) 2010-12-22
KR20110074578A (ko) 2011-06-30
US8148387B2 (en) 2012-04-03
MY161461A (en) 2017-04-14
UA100190C2 (en) 2012-11-26
NZ592062A (en) 2013-03-28
JP5432275B2 (ja) 2014-03-05
MA32776B1 (fr) 2011-11-01
JO2822B1 (en) 2014-09-15
TWI422587B (zh) 2014-01-11
EA018947B1 (ru) 2013-11-29
US20100120801A1 (en) 2010-05-13
CY1113409T1 (el) 2016-06-22
CN102216302A (zh) 2011-10-12
TN2011000207A1 (en) 2012-12-17
RS52520B (sr) 2013-04-30
AU2009314324A1 (en) 2010-05-20
CA2743019A1 (en) 2010-05-20
EP2358710B1 (en) 2012-08-15
DK2358710T3 (da) 2012-09-03
PL2358710T3 (pl) 2012-12-31
CR20110240A (es) 2011-06-09
TW201022268A (en) 2010-06-16
AU2009314324B2 (en) 2013-06-20
HN2011001247A (es) 2013-05-20
EA201170680A1 (ru) 2011-12-30
IL211940A0 (en) 2011-06-30
WO2010056563A1 (en) 2010-05-20
HRP20120738T1 (hr) 2012-10-31
PA8846901A1 (es) 2010-06-28
DOP2011000129A (es) 2016-02-29
BRPI0921916A2 (pt) 2015-12-29

Similar Documents

Publication Publication Date Title
ES2391704T3 (es) Inhibidores de cinasa AKT y P70 S6
AU2008251692B2 (en) P70 S6 kinase inhibitors
ES2465094T3 (es) Inhibidores de AKT
KR20240114793A (ko) Kras g12c 억제제
TW202426427A (zh) 用於治療癌症之化合物
HK1158203B (en) Akt and p70 s6 kinase inhibitors